Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies
UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, announced that it has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 (N,N-Dimethyltryptamine or DMT) for the company’s stroke clinical research program.
Tapeworm, Vertigo and Pancreatitis Drugs Are Being Trialled As COVID-19 Treatments
Included in this news roundup is UF startup Algernon Pharmaceuticals's trials with ifenprodil, a drug used to treat vertigo and bird flu. Algernon is testing the drug's efficacy in preventing lung damage and increasing survivability in patients with COVID-19.
Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19
UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, announced that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the company to continue on with the Phase 3 part of the study.
Algernon Pharmaceuticals Lead Drug Ifenprodil Named As Potential COVID-19 Treatment in European Scientific Journal
Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, said that its lead drug candidate Ifenprodil was highlighted in a European... Read More
Algernon Receives Clearance From Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, is pleased to announce that it has received a “No Objection” letter... Read More
Full Interview: Algernon Pharmaceuticals Receives OK From South Korea for Phase Two Study of Ifenprodil
Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, a clinical-stage pharmaceutical development company, joined Steve Darling from Proactive in Vancouver with big news.... Read More
Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, is pleased to announce that it has submitted a Clinical Trial Application... Read More
Full Interview: Algernon Pharmaceuticals Announces Regulatory Submission for COVID-19 Trial in South Korea
Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, a clinical-stage pharmaceutical development company, joined Steve Darling from Proactive Vancouver to discuss another development... Read More
Full Interview: Algernon Pharmaceuticals Updates Phase 2 Human Testing of Ifenprodil for COVID-19
Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, a clinical-stage pharmaceutical development company, joins Steve Darling from Proactive Vancouver to provide an... Read More
Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, is pleased to announce that it has submitted for ethics approval in... Read More
